Healthcare Professionals​

This is an international website for NERLYNX® dedicated to Healthcare professionals ​​

IMPORTANT: the information on this website is based on the European Summary of Product Characteristics. Prescribing Information and indication may vary per country. You must refer to your country prescribing information. Please be aware we do not take responsibility for accessing such information which may not comply with the regulation or usage in your country.

I certify that: 

I am Healthcare Professional inside the EU and I have read the information above​, the Legal Notice and the Privacy Policy

Non Healthcare Professionals

This is an international website for NERLYNX® dedicated to Healthcare Professionals.

I am not a Healthcare Professional inside the EU.


You’ve come this far – don’t stop now. Take one more step for additional protection.

NERLYNX® is indicated for the extended adjuvant treatment of adult patients with early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.

Extended adjuvant treatment with NERLYNX®
reduces the risk of HER2+/HR+ breast cancer recurrence by 51% after 2 years*†‡


Learn about ExteNET
study design and study results.

Learn more


Learn about NERLYNX® common adverse events, diarrhoea management and other safety information.

Learn more


Learn about NERLYNX® recommended
dose and dose adjustments.

Learn more

*Recurrence is defined as an invasive disease event or death.
†NERLYNX® used as extended adjuvant therapy for 12 months following trastuzumab-based therapy completed less than a year ago.
‡At 2 years, in the HER2+/HR+ population subgroup, iDFS = 95.3% in NERLYNX® arm (N=670) versus 90.8% in placebo (N=664).


Contenu de la pop in (ici, un H3)

A noter que le contenu de la pop in est prise en compte pour le SEO.

Il est donc nécessaire de bien baliser les titres. Nous conseillons d'utiliser un H2 ou un H3 (pas de H1).